APS_ACTION
@APS_ACTION
Followers
786
Following
147
Media
57
Statuses
212
APS ACTION is a network of internationally renown physicians & scientists working to find a cure for Antiphospholipid Syndrome or #APS
Joined March 2013
@APS_ACTION 2025 Young Scholar Zeynep Belce Erton from @HSpecialSurgery Presenting her Research During #ICAPA25 (18th International Congress on Antiphospholipid Antibodies, Kyoto, Japan).
0
2
4
@APS_ACTION Scientific Session and Poster Presentations During #ICAPA25 (18th International Congress on Antiphospholipid Antibodies, Kyoto, Japan). Thank you to all the presenters and session participants.
0
1
4
Congratulations to 2025 APSACTION Silvia Pierangeli Young Scholar Award (in collaboration with APS Foundation of America) Recipients: Alice Barinotti, Zeynep Erton, Alex Luta, Liala Moschetti, Andrew Song. During #ICAPA25, Alice and Zeynep received their certificates in person.
0
2
3
Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from APS ACTION. https://t.co/rkHBH5lKTi
pubmed.ncbi.nlm.nih.gov
In our cohort of persistently aPL-positive patients, the mortality rate was 5% after a median follow-up of five years and was highest for patients ≥60 years old at registry entry. History of arterial...
0
0
3
Survey Reveals 60% Satisfaction with DIAPS but Highlights Need for Improvements: https://t.co/ie5SGuuhXf
@APS_ACTION @DorukErkanMD
pubmed.ncbi.nlm.nih.gov
Approximately 60% of respondents were satisfied with DIAPS and its definitions; however, our survey demonstrated that there is substantial room to improve the current damage index for APS. Efforts...
0
1
3
2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification c…
pubmed.ncbi.nlm.nih.gov
2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification criteria solid phase-based antiphospholipid antibody domain-collaborative efforts of...
0
0
0
Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prosp…
pubmed.ncbi.nlm.nih.gov
Fourteen percent of the TAPS patients were not anticoagulated at recruitment. Their recurrent thrombosis risk did not differ compared to matched anticoagulated TAPS patients, supporting the pressing...
0
0
1
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the APS ACTION Clinical …
pubmed.ncbi.nlm.nih.gov
When we analysed aPL-positive patients with no other SARDs, ANA status was not associated with thrombosis or pregnancy morbidity. Interestingly, ANA+ patients showed higher rates of systemic autoim...
0
1
2
Damage Index for Antiphospholipid Syndrome (DIAPS): An Antiphospholipid Syndrome Alliance for Clinical Trials and I…
pubmed.ncbi.nlm.nih.gov
Approximately 60% of respondents were satisfied with DIAPS and its definitions; however, our survey demonstrated that there is substantial room to improve the current damage index for APS. Efforts...
0
1
2
HSS investigators presented new research findings in #antiphospholipidsyndrome at the @ACRheum Convergence 2024 meeting. #ACR24 #HSSRhem @DorukErkanMD @APS_ACTION
https://t.co/B5zCydSIEl
0
3
7
🤔🩸🔮 Rethinking antiphospholipid syndrome to guide future management and research @NatRevRheumatol @DorukErkanMD
https://t.co/i9YezH8mgd
4
32
77
Our most recent publication on thrombosis recurrence and major bleeding risk in non-anticoagulated thrombotic antiphospholipid syndrome patients. We want to thank all APS ACTION members for their contributions.
pubmed.ncbi.nlm.nih.gov
Fourteen percent of the TAPS patients were not anticoagulated at recruitment. Their recurrent thrombosis risk did not differ compared to matched anticoagulated TAPS patients, supporting the pressing...
0
6
7
ICYMI: In this #RPTH Commentary @crowthrm and @DorukErkanMD discuss the new ACR/EULAR 2023 #Antiphospholipid Syndrome classification and how it may be applied across different clinical scenarios! Read here➡️:
rpthjournal.org
Antiphospholipid antibody syndrome (APS) continues to pose challenges in clinical practice, mainly due to the multifactorial nature of thrombosis and pregnancy morbidity and the lack of reliable...
0
7
14
#ACR23 Recap: @dorukerkanmd and @jasonsknight explained the antiphospholipid syndrome classification criteria developed by the ACR and EULAR. Read more in ACR Convergence Today → https://t.co/IiMeKjSl2U
0
8
20
Antiphospholipid Syndrome Diagnosis versus Classification. What is the Difference? The answer is in this recently updated @HSpecialSurgery Top 10 Series Patient Web Article https://t.co/BFM3LMoMda
hss.edu
Antiphospholipid syndrome (APS): The difference between classification criteria for medical research versus diagnosis criteria for clinical disease management.
0
34
78
Today we have award-winning #APS researcher @DorukErkanMD with us, who explains the importance of creating new classification criteria for APS & what the proper use of them ought to be! Listen → https://t.co/TU8q0CZGRm
#ACR23
1
8
19
@APS_ACTION Core Laboratories Presented at #ACR23 Their Performance Assessment of LA Testing Using TSVT/ECT. https://t.co/XrgY2AUdtT.
0
1
4
Dr Alexander Pine Presenting at #ACR23 - @APS_ACTION & Yale School of Medicine Collaboration on Antiphospholipid Syndrome and Plasma Proteomic Profiling https://t.co/J2LpiOYxMn
0
1
1
Dr Cecile Yelnik presenting at #ACR23 on Behalf of @APS_ACTION - Antiphospholipid Syndrome (#APS) & Complement Pathway Activation https://t.co/bu014L5U6H.
1
0
6